1126 related articles for article (PubMed ID: 35405385)
41. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
42. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
medRxiv; 2022 Jan; ():. PubMed ID: 35118480
[TBL] [Abstract][Full Text] [Related]
43. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita V; Syed AM; Morris MK; Brazer N; Saldhi P; Garcia-Knight M; Sreekumar B; Khalid MM; Ciling A; Chen PY; Kumar GR; Gliwa AS; Nguyen J; Sotomayor-Gonzalez A; Zhang Y; Frias E; Prostko J; Hackett J; Andino R; Wadford DA; Hanson C; Doudna J; Ott M; Chiu CY
Cell; 2022 Apr; 185(9):1539-1548.e5. PubMed ID: 35429436
[TBL] [Abstract][Full Text] [Related]
44. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice.
Toomer G; Burns W; Garcia L; Henry G; Biancofiori A; George A; Duffy C; Chu J; Sides M; Muñoz M; Garcia K; Nikolai-Yogerst A; Peng X; Westfall L; Baker R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423193
[TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters.
Plunkard J; Mulka K; Zhou R; Tarwater P; Zhong W; Lowman M; Wong A; Pekosz A; Villano J
mBio; 2023 Apr; 14(2):e0007823. PubMed ID: 37036339
[TBL] [Abstract][Full Text] [Related]
46. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
47. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
48. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model.
Halfmann PJ; Kuroda M; Armbrust T; Accola M; Valdez R; Kowalski-Dobson T; Rehrauer W; Gordon A; Kawaoka Y
Cell Rep; 2022 Feb; 38(7):110394. PubMed ID: 35139368
[TBL] [Abstract][Full Text] [Related]
49. Omicron breakthrough infections in vaccinated or previously infected hamsters.
Zhou J; Sukhova K; Peacock TP; McKay PF; Brown JC; Frise R; Baillon L; Moshe M; Kugathasan R; Shattock RJ; Barclay WS
Proc Natl Acad Sci U S A; 2023 Nov; 120(45):e2308655120. PubMed ID: 37903249
[TBL] [Abstract][Full Text] [Related]
50. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the Pathogenicity of SARS-CoV-2 Delta and Omicron Variants by Analyzing the Expression Patterns of Immune Response Genes in K18-hACE2 Transgenic Mice.
Kuruppuarachchi KAPP; Jang Y; Seo SH
Front Biosci (Landmark Ed); 2022 Nov; 27(11):316. PubMed ID: 36472114
[TBL] [Abstract][Full Text] [Related]
52. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.
Yinda CK; Port JR; Bushmaker T; Fischer RJ; Schulz JE; Holbrook MG; Shaia C; de Wit E; van Doremalen N; Munster VJ
Emerg Microbes Infect; 2021 Dec; 10(1):1284-1292. PubMed ID: 34120579
[TBL] [Abstract][Full Text] [Related]
53. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
Zou J; Xia H; Xie X; Kurhade C; Machado RRG; Weaver SC; Ren P; Shi PY
Nat Commun; 2022 Feb; 13(1):852. PubMed ID: 35140233
[TBL] [Abstract][Full Text] [Related]
54. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
55. Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
Stich M; Benning L; Speer C; Garbade SF; Bartenschlager M; Kim H; Jeltsch K; Tabatabai J; Niesert M; Janda A; Renk H; Elling R; Hoffmann GF; Kräusslich HG; Müller B; Bartenschlager R; Tönshoff B
J Med Virol; 2023 Mar; 95(3):e28582. PubMed ID: 36794653
[TBL] [Abstract][Full Text] [Related]
56. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
[TBL] [Abstract][Full Text] [Related]
57. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD
Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676
[TBL] [Abstract][Full Text] [Related]
58. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
Uraki R; Iida S; Halfmann PJ; Yamayoshi S; Hirata Y; Iwatsuki-Horimoto K; Kiso M; Ito M; Furusawa Y; Ueki H; Sakai-Tagawa Y; Kuroda M; Maemura T; Kim T; Mine S; Iwamoto N; Li R; Liu Y; Larson D; Fukushi S; Watanabe S; Maeda K; Wang Z; Ohmagari N; Theiler J; Fischer W; Korber B; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Mar; 14(1):1620. PubMed ID: 36959194
[TBL] [Abstract][Full Text] [Related]
59. Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
Lemmer Y; Chapman R; Abolnik C; Smith T; Schäfer G; Hermanus T; du Preez I; Goosen K; Sepotokele KM; Gers S; Suliman T; Preiser W; Shaw ML; Roth R; Truyts A; Chipangura J; Magwaza M; Mahanjana O; Moore PL; O'Kennedy MM
Vaccine; 2024 Feb; 42(4):738-744. PubMed ID: 38238112
[TBL] [Abstract][Full Text] [Related]
60. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
Stauft CB; Selvaraj P; D'Agnillo F; Meseda CA; Liu S; Pedro CL; Sangare K; Lien CZ; Weir JP; Starost MF; Wang TT
Nat Commun; 2023 Jun; 14(1):3393. PubMed ID: 37296125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
